Xiaojun Chen: Clinical Trials

9 trials sponsored by Xiaojun Chen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 active not recruiting, 2 completed, 1 terminated. 7 Phase 2, 7 Phase 3, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 27Recruiting 3, Active not recruiting 1, Completed 1, Terminated 1, Withdrawn 1
Phase 37Recruiting 3, Active not recruiting 1, Completed 1, Terminated 1, Withdrawn 1
Not applicable1Active not recruiting 1

Follow Xiaojun Chen: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
GnRHa, Letrozole 2.5mg, Diane-35 - Endometrial Neoplasms, Atypical Endometrial Hyperplasia
Phase 2 / Phase 3RecruitingXiaojun Chen802022-07-132026-09-10
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
GnRH antagonist, Letrozole 2.5mg - Endometrial Neoplasms, Atypical Endometrial Hyperplasia
Phase 2 / Phase 3RecruitingXiaojun Chen292022-07-132026-09-10
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
GnRH antagonist, Letrozole 2.5mg - Atypical Endometrial Hyperplasia, Progesterone Resistance
Phase 2 / Phase 3Active not recruitingXiaojun Chen292022-07-132025-08-11
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet, Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg - Atypical Endometrial Hyperplasia, Fertility Issues
Phase 2 / Phase 3RecruitingXiaojun Chen1722022-06-132026-06-04
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet - Endometrial Carcinoma, Obese
Phase 2 / Phase 3TerminatedXiaojun Chen82022-05-012026-06-04
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
Liraglutide Injection, Megestrol Acetate 160 MG - Atypical Endometrial Hyperplasia, Obese
Phase 2 / Phase 3WithdrawnXiaojun Chen2021-03-202024-09-26
Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus
sentinel lymph node sampling (SLN), pelvic lymphonodectomy (PLN) - Middle-high Risk Endometrial Cancer, Sentinel Lymph Node Sampling
Not applicableActive not recruitingXiaojun Chen7802020-02-132026-05-12
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
Medroxyprogesterone Acetate, Dydrogesterone 10 MG - Endometrial Hyperplasia Without Atypia
Phase 3CompletedXiaojun Chen4712019-02-262023-02-17
Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Megestrol acetate and metformin, Megestrol acetate - Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma
Phase 2CompletedXiaojun Chen1502013-10-012021-09-14

Conditions studied

Endometrial Hyperplasia (6)  ·  Obesity (5)  ·  Endometrial Neoplasms (3)  ·  Infertility (3)  ·  Progesterone Resistance (3)  ·  Overweight (2)

Interventions

Megestrol Acetate (4)  ·  Letrozole (3)  ·  LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- (2)  ·  Tablets (2)  ·  Cyproterone acetate, ethinyl estradiol drug combination (1)  ·  Dydrogesterone (1)  ·  Levonorgestrel (1)  ·  Liraglutide (1)  ·  Medroxyprogesterone Acetate (1)  ·  Metformin (1)

Countries

China (8)

Results publications

PMID 34085796